February 28-29, 2008
Gaithersburg Marriott Washingtonian Center
Gaithersburg, MD
The iSBTc Oncology Biologics Development Primer (OBDP) was a key forum for continuing to explore and discuss best practices for worldwide biologics development. Through the expertise of the invited speakers, panel members and attendees, this rigorous and challenging program curriculum facilitated understanding, open discussion and exploration of the development issues surrounding biologic agents for cancer.
iSBTc developed the OBDP to meet the needs of the biological therapy community by educating physicians and researchers on the worldwide regulatory paths for biological therapy development. Further, through facilitating collaborative interactions between regulators, pre-clinical scientists, clinical investigators and industry, the iSBTc Oncology Biologics Development Primer helped ensure that active, innovative new therapies are rapidly and appropriately moved into worldwide clinical testing.
Target Audience:
Physicians and scientists in academia, industry and regulatory agencies with an interest in the strategic, pre-clinical, clinical and regulatory aspects of efficient oncology biologics development.
Topics to be Addressed: (Click here for a detailed schedule)
The OBDP was Supported by:
![]() |
![]() |
![]() |